Cancers | Free Full-Text | Longitudinal Humoral and Cellular Immune Responses Following SARS-CoV-2 Vaccination in Patients with Myeloid and Lymphoid Neoplasms Compared to a Reference Cohort: Results of a Prospective Trial of
Pharmaceutics | Free Full-Text | Potential of Microneedle Systems for COVID-19 Vaccination: Current Trends and Challenges
PUBLIC HEALTH
Pharmaceutics | Free Full-Text | Potential of Microneedle Systems for COVID-19 Vaccination: Current Trends and Challenges
Items where Year is 2021 - SORA
1 PERFORMANCE REPORT FOR FEDERAL AID GRANT F-63-R, SEGMENT 12 2021 MARINE AND ESTUARINE FINFISH ECOLOGICAL AND HABITAT INVESTIGA
PUBLIC HEARINGS AND MEETINGS
Special Reports, Mines and Quarries: 1902
Pharmaceutics | Free Full-Text | Potential of Microneedle Systems for COVID-19 Vaccination: Current Trends and Challenges
Pharmaceutics | Free Full-Text | Potential of Microneedle Systems for COVID-19 Vaccination: Current Trends and Challenges
Cancers | Free Full-Text | Longitudinal Humoral and Cellular Immune Responses Following SARS-CoV-2 Vaccination in Patients with Myeloid and Lymphoid Neoplasms Compared to a Reference Cohort: Results of a Prospective Trial of
Pharmaceutics | Free Full-Text | Potential of Microneedle Systems for COVID-19 Vaccination: Current Trends and Challenges
Items where Year is 2021 - SORA
PUBLIC HEARINGS AND MEETINGS
Pharmaceutics | Free Full-Text | Potential of Microneedle Systems for COVID-19 Vaccination: Current Trends and Challenges
Items where Year is 2021 - SORA
Vorur | Kringlan
1 PERFORMANCE REPORT FOR FEDERAL AID GRANT F-63-R, SEGMENT 12 2021 MARINE AND ESTUARINE FINFISH ECOLOGICAL AND HABITAT INVESTIGA
Cancers | Free Full-Text | Longitudinal Humoral and Cellular Immune Responses Following SARS-CoV-2 Vaccination in Patients with Myeloid and Lymphoid Neoplasms Compared to a Reference Cohort: Results of a Prospective Trial of
Items where Year is 2021 - SORA
AUTHOR INDEX
Pharmaceutics | Free Full-Text | Potential of Microneedle Systems for COVID-19 Vaccination: Current Trends and Challenges
